Webinar description

This webinar highlights perspectives of researchers, clinicians and patients across Canada on clinical trials as a pathway to access psychedelic therapy. Since the introduction of psilocybin and MDMA to the Special Access Program in 2022, there have been many questions of whether this access program is appropriate for psychedelic therapy. Are clinical trials a better option? What challenges, barriers, opportunities and benefits arise from this pathway? This webinar also explores funding options and the development of a MAPS Canada working group for clinical research development.

    1. Webinar Recording

About this webinar

  • $10.00
  • 1 hour of video content

Panelists

  • Dr. Emma Hapke, MD, FRCPC, psychiatrist, psychotherapist and psychedelic researcher at the University Health Network in Toronto

  • Sonia Brodie, neuroscientist, Director of Growth & Partnerships at CaRe Clinics, and sits on the board of MAPS Canada as Director of Research

  • Pedram Dara, former MDMA-assisted therapy clinical trial participant and director of Psychedelic Lived Experiences

  • Melanie Dignam, MSW, RSW, integrative psychotherapist, clinical trial therapist

  • Erin Prosk, MSC, President and Co-founder Santé Cannabis

Start you learning journey

Enroll today

Categories